Virtual Library
Start Your Search
S. Abdelwahab
Author of
-
+
P2.07 - Poster Session/ Small Cell Lung Cancer (ID 222)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.07-012 - Accelerated Hypofractionated Radiotherapy and Concurrent Etoposide / Cisplatin in Patients with Limited-Disease SCLC (LD-SCLC) (ID 1244)
09:30 - 09:30 | Author(s): S. Abdelwahab
- Abstract
Background:
The optimal TRT dose/fraction for LS-SCLC remains debatable, and due to increasing number of population in Egypt and number of patients as well, so reducing the duration of radiation therapy is favored. This study was conducted using etoposide and cisplatin (EP) concurrently with accelerated hypofractionated thoracic radiation therapy to evaluate the response and toxicity of this protocol in the treatment of patients with limited-disease small cell lung cancer (LD-SCLC).
Methods:
Thirty patients with previously untreated LD-SCLC were enrolled into this study between June 2012 and February 2015. All patients received etoposide 100 mg/m[2 ]days 1 to 3 and cisplatin 25 mg/m[2 ]days 1 to 3 with start of accelerated hypofractionated thoracic radiation therapy on first day of the second cycle of chemotherapy of 55 Gy,2.5 Gy/ fraction over 30 days. Chemotherapy was given 4-6 cycles. Prophylactic cranial irradiation 25 Gy in 10 daily fractions was given for patient who achieved complete remission.
Results:
The median age was 61 years; 28 patients (93%) were men. ECOG PS was 0 in 6 (20%) patients , 1 in 20 (67%) patients and 2 in 4(13%) patients. Five (17%) patients achieved a complete response (CR), 22 (73%) patients achieved a partial response (PR), while 2 patients (7%) had progressive disease (PD) and 1(3 %) patients achieved stable disease; therefore, the overall response rate was 90%. The median survival time was 26.4 months and 1- and 2-year survival rates were 78% and 58.3%, respectively. The median progression-free survival (PFS) was 16.7 months, and 1- and 2-year PFS times were 60% and 41.4%, respectively. Among the hematologic toxicities neutropenia was the most prevalent toxicity and it was evident as grade 3-4 in 12 patients (40%). Grade 3-4 Asthenia was the most prevalent nonhematological toxicity, in 12 patients (40%); esophagitis occurred in 7 patients (23%). No treatment-related deaths (due to sepsis or bleeding) were reported in the study.
Conclusion:
Using etoposide and cisplatin concurrently with accelerated hypofractionated thoracic radiation therapy for the treatment of patients with LD-SCLC showed an encouraging outcomes and acceptable toxicity and warrants further research.
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-066 - Bevacizumab Combined with Docetaxel : A Real Active Second Line Regimen in Elderly Patients with Advanced Non-Small Cell Cancer (NSCLC) (ID 1285)
09:30 - 09:30 | Author(s): S. Abdelwahab
- Abstract
Background:
Majority of patients with non-small cell lung cancer (NSCLC) are elderly, and age is known to be an important factor for management and treatment. Elderly are underpresented in cancer research. Therefore, we conducted this phase II study aiming at assessing the efficacy and safety of adding bevacizumab to docetaxel as a second line treatment of elderly patients with advanced non squamous NSCLC
Methods:
Twenty five previously treated elderly patients with advanced non squamous NSCLC (stage III, IV) were enrolled into this study between May 2011 and May 2014. All patients received docetaxel 60 mg/m[2] followed by bevacizumab 15mg/kg, both agents were given via I.V infusion on day 1 and the cycle was repeated every 21 days until disease progression or unacceptable toxicity developed.
Results:
The median age was 70 years old (range 65-79 years); 19 (76%) patients were men; ECOC PS was 0 in 6 (24%) patients, 1 in 12 (48%) patients and 2 in 7 (28%) patients. The objective response rate was 60%, while disease control rate was 84%.The median progression-free survival time was 7 months, while the median overall survival time was 19.8 months. Grade 3/4 neutropenia had been recorded in 18(72%) patients, and grade 3/4 fatigue had occurred in 5(20%) patients. No cases of severe bleeding nor treatment-related deaths had been reported in this study.
Conclusion:
Bevacizumab added to docetaxel showed a real activity as a second line treatment in previously treated elderly patients with advanced NSCLC and has an acceptable toxicity.
